Healthpeak Properties heads into its Q2 earnings release today with options positioning locked at a historically bullish extreme — the third consecutive preview to flag this same tension, and it has only sharpened.
The put/call ratio remains pinned near its year-low at 0.23, two standard deviations below the 20-day average of 0.38. Call buyers have dominated the options market for days without let-up. What has shifted since yesterday's preview is the price: DOC bounced 0.8% on Wednesday to $21.79, clawing back some of Tuesday's sector-wide slide. The broader healthcare REIT complex fell hard on the week — ARE dropped 9.5%, LTC fell 8.1%, and HR shed 7.3% — making DOC's relative resilience notable. Short interest is a non-story here: at 3.3% of the float with borrowing costs below 0.41% and availability extraordinarily loose, there is no short-side pressure worth flagging.
The analyst community has been broadly constructive ahead of this release, though the tone is measured rather than enthusiastic. Wells Fargo and UBS raised targets in July while holding neutral-leaning ratings. Mizuho and BMO Capital sit at $24 targets with Outperform ratings, against a consensus mean near $22.55 — a modest premium to yesterday's close. The bear case centers on lab tenant credit risk and weak leasing momentum, with one downgrade earlier in the summer citing a compressed FFOPS growth outlook through 2027. The bull case leans on a diversified portfolio of roughly 700 properties and new development projects that are largely pre-leased and targeting mid-7% stabilized yields. The company's EPS surprise history ranks in the 98th percentile, a record that has set a high bar for this print.
A second-quarter note from earlier this week flagged same-property NOI growth of 2.1%, which offset some concern over rising senior housing operating costs. Guidance was maintained. The print will test whether that stability is enough to satisfy call buyers who have stayed aggressively positioned through three straight weeks of sector weakness — and whether DOC's medical office and life science mix can sustain NOI momentum as lab leasing headwinds persist.
See the live data behind this article on ORTEX.
Open DOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
